Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who relapsed following first-line treatment had higher rates of healthcare utilization and greater costs than the patients who had not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback